KL 1333

Drug Profile

KL 1333

Alternative Names: KL1333; NQO1 substrate - KT&G Life Sciences

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KT&G Life Sciences
  • Developer Yungjin Pharm Co
  • Class Small molecules
  • Mechanism of Action NQO1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Mitochondrial disorders

Most Recent Events

  • 08 Nov 2017 The Committee for Orphan Medicinal Products of the EMA recommends orphan drug designation for KL 1333 in European Union for Mitochondrial disorders
  • 27 Jun 2017 Phase-I clinical trials in Mitochondrial disorders (In volunteers) in South Korea (PO) (NCT03056209)
  • 02 May 2017 KL 1333 licensed to NeuroVive worldwide (except Japan and Korea)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top